drugset / Trial / NCT02011945
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find a dose of Nivolumab that can be safely added to Dasatinib in patients with Chronic Myeloid Leukemia.
Timeline
- Start
- 2014-02-07
- Primary completion
- 2018-12-26
- Completion
- 2018-12-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | — |
| Subject | dasatinib anhydrous | Small molecule | 140 mg | — |